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Key Points
• Strategies to minimize
GVHD are essential if
URD SCT is to be
considered with cura-








We report results of a phase 1 multicenter stem cell transplantation (SCT) trial from HLA-
matched (n 5 7) or one-antigen–mismatched (n 5 7) unrelated donors (URD) using bone
marrow or cord blood as stem cell source, following reduced-intensity conditioning (RIC) in
severe sickle cell disease (SCD). Conditioning included distal alemtuzumab, fludarabine, and
melphalan (matched donors), with thiotepa (mismatched donors). Abatacept, a selective
inhibitor of T cell costimulation, was added to tacrolimus and methotrexate as graft-versus-
host disease (GVHD) prophylaxis to offset GVHD risks, and was administered for longer
duration in bone marrow recipients than in cord blood recipients because of increased
incidence of chronic GVHD with bone marrow. Median age at transplant was 13 years
(range, 7-21 years). The incidence of grades II to IV and grades III to IV acute GVHD at day
1100 was 28.6% and 7%, respectively. One-year incidence of chronic GVHD was 57% and
mild/limited in all but 1 patient who received abatacept for a longer duration. Only 1 patient
developed reversible posterior encephalopathy syndrome and recovered. With a median
follow-up of 1.6 years (range, 1-5.5 years), the 2-year overall and disease-free survival was
100% and 92.9%, respectively. The encouraging results from the phase 1 portion of this RIC
SCT trial, despite risk factors such as older age, URD, and HLA-mismatch, support further
evaluation of URD SCT in clinical trial settings. The phase 2 portion of the trial is in progress.
This trial was registered at www.clinicaltrials.gov as NCT03128996.
Introduction
Allogeneic stem cell transplantation (SCT) from HLA-matched sibling donors has excellent disease-free
survival (DFS) of.90% in children with sickle cell disease (SCD) but is limited by donor unavailability in
.80% of eligible patients.1 Unrelated donors (URD) are potential alternate donor sources. Patients of
African origin have a 19% chance of finding fully (8/8) HLA-matched, but a 57% chance of finding
minimally mismatched (7/8), URD in donor registries.2 However, SCT from URD bone marrow has been
associated with high risks of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host
disease (cGVHD) and consequent mortality in the first URD SCT trial for SCD performed following
reduced-intensity conditioning (RIC) designed to offset high-dose chemotherapy-related organ
toxicities. The 2-year overall survival (OS) was 79% (95% confidence interval [95% CI], 59%-90%)
suggesting caution for this approach.3 aGVHD also complicated unrelated cord blood transplantation
with RIC.4,5 Further, graft-versus-host disease (GVHD) risks rise exponentially with recipient age
.12 years irrespective of donor source.3,6,7 African Americans, encompassing most SCD patients, have
a higher risk of GVHD.8-10 GVHD prophylaxis or treatment with corticosteroids also increase
hypertension-related complications such as posterior reversible encephalopathy syndrome (PRES) and
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cerebral hemorrhage, complications that SCD patients are highly
susceptible for at baseline.3,11 Thus, it is critically important to
prevent GVHD and limit complications to successfully expand this
curative therapy in SCD patients.
Abatacept is a fusion protein that selectively inhibits T‐cell costimu-
lation by binding to CD80/CD86 on antigen‐presenting cells and
blocking CD28-mediated signaling.12 A first-in-human trial of
abatacept prophylaxis after SCT for malignant disorders safely
protected against aGVHD, earning the agent a breakthrough
designation for this indication from the US Food and Drug
Administration and provided background for this approach.13
In the phase 2 portion of the trial, grade 3 to 4 aGVHD decreased
to 2.3% following URD SCT when short-term abatacept was
administered until day128 in 4 doses, but no benefit was noted
on cGVHD following HLA-mismatched SCT compared with
controls14. We report the results of the phase 1 portion of a trial
(NCT03128996) of URD SCT in recipients#21 years with severe
SCD using the RIC previously reported, followed by tacrolimus,
methotrexate, or mycophenolate (in cord blood recipients), and
abatacept as GVHD prophylaxis.5 The primary end points were
engraftment, OS, and DFS at 1 year. Secondary end points
included the kinetics of engraftment, nature and severity of GVHD,
disease symptoms, organ toxicities, infections, and immune
reconstitution for 2 years.
Methods
The institutional review board at each participating institution
approved the protocol. Between August 2016 and June 2018, 14
SCD patients, age 7 to 21 years (median, 13 years), with stroke
(n5 6),$3 severe vaso-occlusive pain crises per year (n5 6), or$2
acute chest syndrome episodes per year (n 5 5) underwent URD
SCT at 5 participating centers after consent. Seven received 8/8
HLA-matched (-A, -B, - C, and -DRB1) bone marrow, 5 received
7/8 matched bone marrow, and 2 received 5/6 matched (-A, -B,



























1 10/F Stroke Bone
marrow/A
antigen
4* 95 0/limited (mild) 5.5 SJS/resolved Off (1 y, 9 mo) 100/100
2 13/F VOE Bone marrow/
DRB1 antigen
4* 100 Gr 1/extensive
(severe)
4.8 PRES/resolved On 100/70
3 21/M Stroke Bone marrow/
none
8 95 0/limited (mild) 4.5 Pancreatic
insufficiency/
ongoing
Off (1 y) 100/100
4 18/F VOE Bone marrow/
C allele
8 100 0/limited (mild) 3.3 None Off (1 y, 1 mo) 80/100
5 19/M VOE, ACS Bone
marrow/A
allele
8 100 Gr 2/0 2.9 AKI/resolved Off (1 y, 1 mo) 90/100
6 7/M ACS Bone marrow/
none
8 96 0/limited (mild) 2.1 None Off (1 y, 5 mo) 90/100
7 18/F VOE, ACS Bone
marrow/A
antigen










8 96 0/limited (mild) 1.5 None Off (1 y) 100/100
9 9/M VOE, ACS Cord blood/
DRB1




Off (1 y, 6 mo) 90/90
10 8/F Stroke Bone
marrow/B
allele
8 100 Gr 4/limited (mild) 1.5 None On 80/90
11 13/F Stroke Bone marrow/
none
4 0 NE GR None NE 90/90
12 21/M Stroke Bone marrow/
none
8 100 0/0 1.4 None Off (1 y) 100/100
13 2/M ACS Cord blood/B
antigen
4 100 0/0 1 AKI/resolved Off (1 y) 100/100
14 7/M Stroke Bone
marrow/A
antigen
8 100 0/0 1 None Off (1 y) 70/90
ACS, acute chest syndrome; AKI, acute kidney injury; F, female; Gr, grade; GR, graft rejection; M, male; NE, not evaluable; NIH, National Institutes of Health; RBC, red blood cell; SJS,
Stevens-Johnson syndrome; VOE, vaso-occlusive episodes.
*The first 2 patients were treated on an earlier version of the protocol and received 4 doses of abatacept. Abatacept administration was extended to 8 doses in bone marrow transplants
subsequently.
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and –DRB1) cord blood (Table 1). Hemoglobin S was ,30%
prior to conditioning in all patients. RIC included hydroxyurea
(days 250 to 221), distal alemtuzumab (days 222 to 219),
fludarabine (days 28 to 24), and melphalan (day 23) as
previously described.3 Thiotepa (8 mg/kg) on day 24 was
added to the regimen for mismatched bone marrow and cord
blood products.5 GVHD prophylaxis included tacrolimus and
short-course methotrexate (bone marrow) or mycophenolate
mofetil (cord blood) as previously described.3 Abatacept
(10 mg/kg) was administered intravenously on days 21, 15,
114, 128, 1100, 1180, 1270, and 1365. Cord blood
transplants reported in this study received abatacept until day
128 (4 doses). After April 2019, as a result of aGVHD risks we
reported with unrelated cord blood in the first few months post-
SCT but lower cGVHD risks, the protocol was changed so that
abatacept doses are continued only until day 1100 in cord
blood transplants.5,15,16 Abatacept dosing was extended in
bone marrow transplant recipients as an amendment after the
first 2 patients, to evaluate the possible benefit of extended use
on cGVHD, a complication to which this population is highly
susceptible (Table 1). The interval between doses with the
extended use was based on the assumption that proliferation of
alloreactive T cells in damaging numbers would have a lag
period after wash-out of a previous dose, and balancing the
interval between doses would be advantageous for immune
reconstitution. Supportive care included hypertension control,
seizure prophylaxis, and hemoglobin/platelet count mainte-
nance.3 GVHD was graded according to previously published
criteria.17 The probability of OS and DFS was estimated from
the time of transplantation using Kaplan-Meier product-limit
estimates.
Results and discussion
Patient demographics, transplantation details, and outcomes are
summarized in Table 1. All patients had risk factors for transplant-
related morbidity and/or mortality on the basis of age (n 5 10),
URD source, and HLA-mismatch (n 5 7).18-21 The median
number of total nucleated and CD341 cells per kilogram of body
weight was 3.0 3 108 (range, 0.75 3 108 to 5.5 3 108) and
3.36 3 106 (range, 0.19 3 106 to 4.5 3 106), respectively. At
a median follow up of 1.6 years (range, 1-5.5 years), 13 of 14
recipients had stable donor engraftment. One patient with
cytomegalovirus (CMV) reactivation had secondary graft re-
jection on day 130. This patient subsequently rejected another
URD graft following myeloablative conditioning and received
a haploidentical transplant with donor engraftment at early
follow-up. The 2-year probability of OS and DFS was 100% and
92.9%, respectively (Figure 1A-B). The median time to neutrophil
and platelet (.503 103/mL) engraftment was 14 days (range,
10-24 days) and 19.5 days (range, 16-39 days), respectively. All
engrafted patients had .95% donor chimerism at their last
evaluation. No patient had SCD manifestations such as vaso-
occlusive episodes, acute chest syndrome, or central nervous
system events or radiologic progression in the follow-up period
post-SCT.
The incidence of grade II to IV aGVHD at day 1100 was 28.6%.

















































































































Figure 1. Probability of survival and serial immune reconstitution. (A) Five-year OS, 100%. (B) Five-year DFS, 92.9%. Dots depict a censored event. Recovery of
CD41 T cells (C), CD81 T cells (D), CD191 B cells (E), and CD16/561 NK cells (F) presented as absolute numbers on days 1100, 1180, and 1365. Cut offs for normal
values are indicated with horizontal dashed lines.
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were treated with topical therapy. One developed grade 4 GVHD
of the gut, and required systemic therapy until resolution. All
patients continued GVHD prophylaxis as dictated by the trial.
Seven patients developed localized skin rash or oral plaques in
the first year that responded to topical therapy. Systemic immune
suppression wean was commenced 9 to 12 months post-SCT
successfully per protocol. Only 1 of 9 patients who received
URD bone marrow and abatacept doses beyond day 1100
developed extensive cGVHD affecting the lung; that patient
continues systemic immune suppression. One patient developed
PRES that was self-limiting, in contrast to 34% reported previ-
ously with URD SCT.3
The sharp decrease in complications is attributed to changes in
GVHD prophylaxis (tacrolimus weaned 9-12 months post-SCT,
deletion of corticosteroid prophylaxis, and addition of abata-
cept). GVHD prophylaxis was modified on the basis of
advantages provided by abatacept’s mechanism of action and
low toxicity in primate models and subsequent clinical trials in
malignant disorders.12,14 The continued risk of cGVHD in the
first 2 participants in this trial prompted an amendment to
extend costimulation blockade with abatacept to 1 year post-
transplant in SCD patients receiving bone marrow products,
though discontinued on day 1100 following cord blood trans-
plants. Another trial is exploring the benefits of intermediate-
duration abatacept on the risk of GVHD in SCD SCT.22 If
successful, this strategy of GVHD prophylaxis avoids exposure
to chemotherapy-based prophylaxis such as high dose post-
SCT cyclophosphamide.23
Abatacept did not hinder donor engraftment. T-cell subsets
gradually recovered after day 1100 to the normal range by
1 year (Figure 1C-F). The pace of immune reconstitution was
robust after 6 months despite the use of abatacept. Asymp-
tomatic CMV reactivation, noted in 8 patients prior to day
1180, responded to antiviral therapy and was concomitant with
graft rejection in 1 patient. Thus, susceptible patients (recipient
seropositive) were at high-risk for early CMV reactivation during
the most severe period of immune incompetence and could
benefit from prophylaxis if at risk.24 EBV replication noted in 1
patient was asymptomatic and treated with 2 doses of
rituximab. One was treated with 2 doses of rituximab, and the
other received no treatment. EBV replication subsided in both
without symptoms. Additional infections in single patients
included adenovirus viremia, BK viremia, influenza, Salmonella
enteritis, line infection with Fusarium, and methicillin-resistant
Staphylococcus aureus (Table 2); all responded to treatment.
The low GVHD incidence that successfully allowed taper of
systemic immune suppression (Table 1) likely enhanced immune
reconstitution and recovery from infectious complications. Though
infection risks seemed to abate after the initial few months post-
SCT, continued monitoring is prudent until immune suppression is
discontinued.
The most frequent organ toxicity noted was renal dysfunction (n5 3),
which resolved with weaning calcineurin inhibitors. One patient
developed pure red aplasia that was treated with immunoglobulin,
bortezomib, and prednisolone, with resolution. One patient required
cholecystectomy for cholelithiasis. No patient had SCD-related
symptoms post-SCT.
Our preliminary results suggest that this RIC regimen combined
with abatacept-inclusive GVHD prophylaxis protects against trans-
plant complications that contribute to morbidity/mortality after URD
SCT. These results support further study of URD SCT in clinical trial
settings. Phase 2 trials of URD SCT, adding abatacept to standard
GVHD prophylaxis are underway. Safely expanding the donor pool
so SCD patients can benefit from curative intervention with minimal
treatment-related morbidity remains a goal for hematology and
transplant teams.
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Table 2. Etiology and timing of infections posttransplant
Infection type
Infections recorded
0-100 d posttransplant 101-180 d posttransplant 181-365 d posttransplant
Bacterial
Pantoea (1) Klebsiella (1)




Fungal Candida (1) Fusarium (1)
Viral
CMV Adenovirus (1) Influenza (2)
Reactivation (7) Parainfluenza (2) Parainfluenza (1)
BK virus (1) EBV reactivation (2)
Adenovirus (1) Influenza (1)
CMV reactivation (2)
The numbers in parentheses indicate number of patients with the infection.
*Except for Salmonella enteritis, the other bacterial infections were bacteremias diagnosed by blood culture.
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